Product Name: Ranitidine hydrochloride (CAS NO.66357-59-3)

Molecular Formula: C₁₃H₂₃ClN₄O₃S
Molecular Weight: 350.86g/mol
Mol File: 66357-59-3.mol
Einecs: 266-332-5
Appearance: Off-White Crystalline Solid
Melting Point: 134°C (dec.)
Boiling point: 437.1 °C at 760 mmHg
Flash Point: 218.2 °C
Water Solubility: H₂O: 1.8 mg/mL
Sensitive: Hygroscopic
Enthalpy of Vaporization: 69.37 kJ/mol
Vapour Pressure: 7.66E-08 mmHg at 25°C
Product Categories: Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals; Sulfur & Selenium Compounds; AntagonistsEPA; NeatsCell Signaling Enzymes; 1694 Pharmaceuticals&Personal Care Products; Histaminergics; Neurotransmitters; Substrates; Xenobiotics and Drug Metabolism

 Ranitidine hydrochloride (CAS NO.66357-59-3) was developed by Glaxo in an effort to match the success of Smith, Kline & French (prior to the merger of the two companies into GlaxoSmithKline) with the first histamine H2-receptor antagonist cimetidine. Ranitidine was the result of a rational drug-design process using what was by then a fairly refined model of the histamine H2-receptor and quantitative structure-activity relationships.
Glaxo refined the model further by replacing the imidazole-ring of cimetidine with a furan-ring with a nitrogen-containing substituent, and in doing so developed ranitidine. Ranitidine was found to have a far-improved tolerability profile, longer-lasting action, and ten times the activity of cimetidine. Ranitidine has 10% the affinity that cimetidine has to CYP450 so it causes fewer side effects, but other H₂ blockers famotidine and nizatidine have no CYP450 significant interactions.
Ranitidine was introduced in 1981 and was the world's biggest-selling prescription drug by 1988. It has since largely been superseded by the even more effective proton pump inhibitors, with omeprazole becoming the biggest-selling drug for many years. When omeprazole and ranitidine were compared in a study of 144 people with severe inflammation and erosions or ulcers of the esophagus, 85 percent to those treated with omeprazole healed within eight weeks, compared to 50 percent of those given ranitidine. In addition, the omeprazole group reported earlier relief of heart burn symptoms.

 Ranitidine hydrochloride (CAS NO.66357-59-3) is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in treatment of peptic ulcer disease  and gastroesophageal reflux disease . Ranitidine is also used alongside fexofenadine and other antihistamines for the treatment of skin conditions such as hives. Ranitidine HCl is marketed under the brand name Zinetac or Zantac.
Outside of the United States, ranitidine is combined with bismuth  as a citrate salt , to treat Helicobacter pylori infections. This combination is usually given with clarithromycin, an antibiotic.

Safety Information of Ranitidine hydrochloride (CAS NO.66357-59-3):
Risk Statements: 20/21/22  
20:  Harmful by inhalation 
21:  Harmful in contact with skin 
22:  Harmful if swallowed 
Safety Statements: 22-24/25
22:  Do not breathe dust 
24:  Avoid contact with skin 
25:  Avoid contact with eyes 

 Ranitidine hydrochloride ,its CAS NO. is 66357-59-3,the synonyms is 1,1-Ethenediamine, N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-, monohydrochloride ; Alvidina ; Apo-Ranitidin ; Coralen ; Digestosan ; Ergan ; Esofex ; Fendibina ; Gastridina ; Gastrolav ; Kuracid ; Label ; Mideran ;N-(2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine, hydrochloride ; Neugal ; Noktome ; Normon ; Novo-Radinine ; Ranitidin Helvepharm ; Ulcolind Rani ; Zantac in plastic container .